Since 1992, the FDA has granted accelerated approval to drugs based on so-called surrogateendpoints, or initial measures that suggest the drug will make real improvements in patient health.
Thus, surrogateendpoints like response rate and progression-free survival are commonly accepted, although all parties involved realize the risk involved.